mRNA adjuvant boosts T-cell response to cancer vaccines
Researchers at MIT and other institutions developed an mRNA-based adjuvant that enhances T-cell activity against tumors. In mouse models, the approach slowed or eliminated several cancer types, and it also improved the effectiveness of checkpoint inhibitor drugs. The technique could lead to more potent cancer vaccines and stronger immune responses to infectious diseases.
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Amping up T cells to target cancer.” Browse more stories.